Maximum tumor size reduction from baseline. Includes patients with postbaseline tumor measurements (n = 74). Five patients are not included in the figure for the following reasons: 1 patient with plasmablastic lymphoma was determined to have clinical PD per investigator and had no postbaseline scans; 1 PTLD patient’s response was determined to be not evaluable because the patient had no measureable baseline lesions; and 3 patients in the combination therapy cohort were excluded because 1 patient received 1 cycle of treatment, then withdrew consent; 1 died as a result of related toxic epidermal necrolysis after 2 cycles with no response assessment; and 1 was excluded because of prohibited therapy prior to ending treatment of progression (no postbaseline scans).